S14 Ep9: Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS
OncLive® On Air - Un pódcast de OncLive® On Air
Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.
